OneDigital Investment Advisors LLC cut its stake in shares of Amarin Corporation PLC (NASDAQ:AMRN - Free Report) by 10.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 656,705 shares of the biopharmaceutical company's stock after selling 76,600 shares during the quarter. OneDigital Investment Advisors LLC owned 3.20% of Amarin worth $294,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. AXA S.A. acquired a new position in shares of Amarin during the 4th quarter worth about $480,000. Raymond James Financial Inc. acquired a new stake in Amarin in the fourth quarter valued at approximately $343,000. Quinn Opportunity Partners LLC lifted its holdings in shares of Amarin by 85.2% during the fourth quarter. Quinn Opportunity Partners LLC now owns 1,106,539 shares of the biopharmaceutical company's stock worth $537,000 after purchasing an additional 508,989 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in Amarin in the fourth quarter valued at $171,000. Finally, Jane Street Group LLC bought a new stake in Amarin in the fourth quarter valued at $130,000. Institutional investors and hedge funds own 22.25% of the company's stock.
Amarin Trading Down 1.9%
NASDAQ:AMRN traded down $0.31 on Tuesday, reaching $15.79. 88,576 shares of the stock traded hands, compared to its average volume of 83,458. The company has a market capitalization of $327.01 million, a price-to-earnings ratio of -4.34 and a beta of 0.82. Amarin Corporation PLC has a 12 month low of $7.08 and a 12 month high of $17.49. The company's fifty day simple moving average is $13.03 and its 200 day simple moving average is $11.23.
Amarin (NASDAQ:AMRN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.02. Amarin had a negative net margin of 41.07% and a negative return on equity of 17.21%. Equities analysts anticipate that Amarin Corporation PLC will post -0.15 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on the stock. The Goldman Sachs Group boosted their price target on shares of Amarin from $7.00 to $12.00 and gave the stock a "sell" rating in a report on Wednesday, June 25th. Wall Street Zen raised shares of Amarin from a "sell" rating to a "hold" rating in a research report on Thursday, May 8th.
Read Our Latest Report on Amarin
About Amarin
(
Free Report)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Featured Articles
Before you consider Amarin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.
While Amarin currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
